12:00 AM
 | 
Nov 18, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Sofosbuvir: Phase II data

Data from 39 evaluable patients with undetectable HCV RNA levels prior to liver transplantation in the open-label, international Phase II Study 2025 showed that once-daily 400 mg sofosbuvir plus ribavirin for up to 48 weeks or until transplantation led to undetectable HCV RNA levels at 12 weeks post-transplantation in 64% of patients. Seven patients had recurrence and 1 patient died of primary graft non-function after re-transplantation. The trial enrolled 61 treatment-naïve and treatment-experienced patients with HCV...

Read the full 360 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >